NEW YORK, March 14, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics
– Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0453472/Methicillin-Resistant-Staphylococcus-Aureus-MRSA-Therapeutics—Pipeline-Assessment-and-Market-Forecasts-to-2017.html
Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics
– Pipeline Assessment and Market Forecasts to 2017
SummaryGlobalData, the industry analysis specialist, has
released its new report, “Methicillin-Resistant Staphylococcus
Aureus (MRSA) Therapeutics – Pipeline Assessment and Market
Forecasts to 2017”. The report is an essential source of
information and analysis on the global MRSA market. The report
identifies the key trends shaping and driving the global MRSA
market. The report also provides insights on the prevalent
competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market
leaders. Most importantly, the report provides valuable insights on
the pipeline products within the global MRSA sector. This report is
built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
The global MRSA market was valued at $900m in 2010 and is
forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.8%
for the next seven years to reach $1,249m by 2017. The gro
‘/>”/>
SOURCE
